{"url_path":"/sec/slxn/8-k/2026-07-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","accession_number":"0001178913-26-003551","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":64,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits\n\n[3.1](exhibit_3-1.htm) [Memorandum Amendment, dated July 20, 2026](exhibit_3-1.htm)\n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be\nsigned on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nSILEXION THERAPEUTICS CORP\n\n \n\n \n\nDate: July 21, 2026\n\nBy:\n\n/s/ Ilan Hadar\n\n \n\nName:\n\nIlan Hadar\n\n \n\nTitle:\n\nChief Executive Officer"}